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Introduction: The preclinical efﬁcacy and safety of rVIII-SingleChain (CSL627), a novel recombinant
single-chain factor VIII, was assessed in a series of animal studies.
Materials and Methods: In the tail-clip bleeding model, hemophilia A mice were injected with escalating doses
(1–150 IU/kg) of rVIII-SingleChain, B-domain deleted (BDD) rFVIII (ReFacto AF®), or full-length rFVIII
products (Advate®, Helixate®). Total blood loss and the percentage of animals in which hemostasis occurred
were assessed in this observer-blinded, randomized study. In a second non-randomized study in hemophilia
A mice, thromboelastographic analysis, thrombin generation, and activated partial thromboplastin time as-
says were performed. General safety and toxicity were assessed in three animal species, including determi-
nation of the prothrombotic potential of rVIII-SingleChain in a rabbit venous thrombosis model.
Results: Under acute bleeding conditions, the effect of rVIII-SingleChain on total blood loss and hemostasis
was indistinguishable from BDD and full-length rFVIII. rVIII-SingleChain and full-length rFVIII (both 20 IU/kg)
corrected thromboelastographic parameters, activated partial thromboplastin time, and thrombin generation
to a similar degree in hemophilia A mice. In a thrombosis model, the effect of rVIII-SingleChain on thrombus
incidence was non-signiﬁcant and comparable to BDD rFVIII at doses up to 500 IU/kg. Treatment with
rVIII-SingleChain did not cause anaphylactic reaction or local intolerance in safety and toxicity studies, and
demonstrated an excellent overall safety proﬁle.
Conclusions: rVIII-SingleChain showed convincing hemostatic efﬁcacy and excellent tolerability in animal studies,
warranting continued investigation in human Phase I/III trials (AFFINITY).© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
The management of bleeding disorders has improved dramatically
in recent decades, resulting in great beneﬁts for people with these
conditions in terms of quality and length of life [1]. Hemophilia A istivated prothrombin complex
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blished by Elsevier Ltd. All rights rethe most common form of hemophilia [2]. The mainstay of clinical
management is on-demand or prophylactic replacement of deﬁcient
factor VIII (FVIII) with plasma-derived or recombinant factors [3–5].
Since recombinant FVIII (rFVIII) was ﬁrst used in the 1980s, continu-
ing changes in replacement therapy have led to recombinant prod-
ucts being devoid of animal and human-derived proteins in the cell
culture and formulation processes [6].
Despite effective replacement therapies, which have provided a nor-
mal or near-normal life expectancy for most people with hemophilia A,
key challenges remain [7]. The development of inhibitory antibodies
during FVIII replacement therapy is amajor problem for up to 30% of pa-
tients using these products, rendering therapy ineffective and increas-
ing the risk of bleeding complications [8–10]. Furthermore, patients
who undergo a prophylaxis regimen usually require three doses per
week due to the short half-life of FVIII [11,12]. Thus, there is an unmet
medical need for rFVIII therapy that offers reduced potential to elicit in-
hibitory antibodies combined with a more convenient dosing regimen.
rVIII-SingleChain is a novel recombinant single-chain FVIII con-
struct comprising covalently bonded heavy and light chains. The acti-
vated form of rFVIII (rFVIIIa) produced from rVIII-SingleChain isserved.
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FVIII [13]. This novel single-chain design could allow for beneﬁcial
features such as high intrinsic stability and molecular integrity, and
faster and enhanced binding to von Willebrand factor (VWF), which
in turn may contribute to a low potential for immunogenicity [1].
Several safety precautions are taken during the manufacture of
rVIII-SingleChain, including two dedicated viral inactivation and remov-
al steps. No human- or animal-derived proteins are added in the fermen-
tation, puriﬁcation, or formulation stages. rVIII-SingleChain is expressed
in Chinese hamster ovary (CHO) cells, which are an established and
standardized cell line for the production of recombinant coagulation fac-
tors. In addition, using CHO cells ensures that post-translational modiﬁ-
cations such as glycosylation occur in a consistent manner [14].
In this series of animal studies, one of the key objectives was to de-
termine the hemostatic efﬁcacy and overall safety proﬁle of rVIII-
SingleChain in a range of animal species in order to guide the clinical
studies (AFFINITY) of this novel rFVIII compound in humans.
Materials and Methods
Preclinical Efﬁcacy: In vivo Characteristics of rVIII-SingleChain vs
Full-Length rFVIII
Animals
Factor VIII-deﬁcient hemophilia A mice [15], bred and supplied by
Charles River Laboratories (Kisslegg, Germany), were aged more than
eight weeks and weighed N19 g.
Tail-Clip Model
Hemostasis was assessed using a subaquatic tail-clip bleedingmodel
in an observer-blinded, randomized (computer-generated pseudo-
random numbers) study. Fifteen minutes before a tail clip, animals
were injected intravenously with rVIII-SingleChain or marketed rFVIII
products (Advate® [Baxter Bioscience, Vienna, Austria], Helixate® [CSL
Behring, Marburg, Germany], or ReFacto AF® [Pﬁzer Inc., Sandwich,
UK]) at doses of 1, 5, 15, 40, 100, or 150 IU/kg. A control group was
injected with vehicle (formulation buffer of rVIII-SingleChain).
The tail was cut with a scalpel knife (start of the observation period)
under deep anesthesia (sodium pentobarbital, 74.5 mg/kg), removing
about 3 mm of the tail tip. Immediately upon tail clipping, the tail tip
was submerged in isotonic saline solution (0.9%), which was kept at
the physiologic body temperature of the mice using a water bath,
until hemostasis occurred. The volume of total blood losswas calculated
over an observation period of 30 minutes, or until hemostasis occurred,
by measuring the hemoglobin present in the isotonic saline (0.9%)
(Sysmex F-820, Sysmex Europe GmbH).
The co-primary endpoints for this study were total blood loss
(hemoglobin content) after tail clip and the percentage of animals in
which hemostasis occurred. The relative potency of rVIII-SingleChain
versus the marketed rFVIII products with respect to total blood loss
was estimated by a pairwise analysis of covariance model with depen-
dent variables of total blood loss and covariates of sex, log dose, and
treatment (rVIII-SingleChain and either Helixate®, ReFacto AF®, or
Advate®). The relative potency of rVIII-SingleChain, full-length rFVIII
(Helixate®, and Advate®) and two-chain BDD rFVIII (ReFacto AF®) for
the percentage of animals in which hemostasis occurred was estimated
in pairwise linear logistic regression models with hemostasis as the de-
pendent variable (no/yes) and covariates of sex, log dose, and treatment
(rVIII-SingleChain and either Helixate®, ReFacto AF®, or Advate®).
Thromboelastography, Thrombin Generation Assay, Activated Partial
Thromboplastin Time, and FVIII Activity
In this non-randomized study in hemophilia A mice, citrated (10%
v/v) FVIII-deﬁcient mouse blood was terminally collected under deep
anesthesia (vena cava puncture) 15 minutes after intravenousinjection of rVIII-SingleChain or full-length rFVIII (Advate®) into the
lateral tail vein (both dosed at a level of 20 IU/kg).
A ROTEG 05 analyzer (Pentapharm GmbH, Munich, Germany)
was used to assess the effects of the test substances on thrombo-
elastographic parameters in citrated whole blood. Coagulation was
activated by recalciﬁcation using star-tem® 20 reagent (0.2 mol/L cal-
cium chloride in HEPES buffer; Tem International GmbH, Munich,
Germany). The thrombin generation assay (TGA) was performed by
calibrated thrombinography (Calibrated Automated Thrombogram
[CAT®], Thrombinoscope, Maastricht, The Netherlands). To induce in-
trinsic activation, samples were incubated with a mixture of phos-
pholipid (Rossix, Mölndal, Sweden) and Pathromtin® SL (Siemens
Healthcare Diagnostics Products GmbH, Marburg, Germany) at 37 °C
for 10 minutes; ﬂuorescence was read for 40–60 minutes. For activat-
ed partial thromboplastin time (aPTT) analysis, samples were incu-
bated with Pathromtin® SL reagent for 2 minutes and analyzed
following addition of calcium chloride solution (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany). The chromogenic
FVIII activity plasma levels were determined using a Coamatic®
Factor VIII test kit (Chromogenix Instrumentation Laboratory SpA,
Milan, Italy). FVIII activity and aPTT measurements were performed
automatically using a coagulation analyzer (BCS® XP, Siemens
Healthcare Diagnostics) after an incubation time of 2 minutes.
Correction of thromboelastographic parameters, including clotting
time (CT), clot formation time (CFT), maximum velocity, alfa angle,
time to maximum velocity, maximum clot formation, and time to
maximum clot formation, was compared between rVIII-SingleChain
and full-length rFVIII. In the thrombin generation assay (TGA), lag
time, endogenous thrombin potential (ETP) (0–20 minutes), throm-
bin peak, and time to thrombin peak were compared between prod-
ucts. aPTT values were compared between vehicle, rVIII-SingleChain,
and full-length rFVIII using the log-transformed data.
Welch’s t-test for unequal variances was used to compare the
thromboelastography, thrombin generation variables, and aPTT values
between the treatment groups. Two-sided 90% conﬁdence intervals
(CIs) for the ratio of the mean values of rVIII-SingleChain and
full-length rFVIII comprised all θ values (where θ represents the hy-
pothesized ratio), for which the null hypothesis:
MEAN rVIII SingleChain½ −θMEAN Advate®
h i
¼ 0
was not rejected at a 10% level by Welch's t-test.
All p-values refer to two-sided null hypotheses.
For statistical analysis of the FVIII chromogenic activity, a two-
component mixture model was ﬁtted to the data, due to some
low outlying values. This model encompassed a normal distribution
representing ordinary measurements and a Weibull distribution
representing outlying data. The mean values of the normal distribu-
tions of the factor VIII groups were compared and a CI of the ratio of
the mean values was derived by applying signed likelihood-ratio
tests.
Safety and Tolerability: rVIII-SingleChain Characteristics in Pivotal Safety
Studies – Good Laboratory Practice-Compliant Toxicology Program in
Three Preclinical Animal Species
Thrombogenicity in Rabbits
The prothrombotic potential of rVIII-SingleChain was assessed in
a rabbit venous thrombosismodel after inducing temporary venous sta-
sis (modiﬁed Wessler test [16]). Male and female New Zealand White
rabbits (2.3–3.1 kg) were randomly allocated according to bodyweight
to treatment groups of six animals (threemales and three females), ex-
cept for the placebo (negative control) group, which contained 12 ani-
mals (six males and six females). rVIII-SingleChain was evaluated at
intravenous doses of 150, 300, 500, and 1000 IU/kg. FEIBA NF 500®
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was included at a dose of 200 IU/kg to act as a positive control.
Two-chain BDD rFVIII (ReFacto AF®) 500 IU/kgwas included as an addi-
tional comparator. The negative control (placebo) group received phys-
iologic saline solution.
After the animals were anesthetized with an intravenous injection
of sodium pentobarbital (31 mg/kg) into the marginal vein of the left
ear, a segment of approximately 1 cm of both jugular veins was
isolated. The study treatment was then administered via the right
marginal ear vein. Stasis was produced in the previously isolated seg-
ment of both jugular veins by ligation with a cotton thread (right
segment ﬁrst and then the left segment) one minute after study treat-
ment administration. The isolated segments of the right and left veins
were transferred to a pre-weighed piece of paper after 10 and 20 mi-
nutes, respectively, to allow examination and evaluation. Thrombi
were left to dry for 24 hours and then weighed.
Thrombosis incidence and thrombus dry weight were assessed as
primary endpoints. The incidence of thrombosis was assessed using a
scoring system of 0–4, where 0 = non-clotted blood, 1 = ﬁbrin net-
works, 2 = ≥1 small thrombi, 3 = non-occlusive thrombus, and
4 = one occlusive thrombus.
The percentage of potentiation of thrombus formation (PTF) was
calculated for each of the different doses of rVIII-SingleChain using
the following formula:
rVIII SingleChain mDWTð Þ− negative control group mDWTð Þ
positive control group mDWTð Þ− negative control group mDWTð Þ  100
Where mDWT is the mean dry weight of thrombus.
When a dry weight of thrombus value of ≤0.1 mg was recorded,
this was considered to be 0 mg because it is at the limit of quantiﬁca-
tion for the balance used.
Scores of thrombus incidence after the different treatments were
compared using the ranked Mann–Whitney test. Statistical differ-
ences between the groups in dry weight of thrombus were assessed
using the Student–Newman–Keuls test.
Acute and Sub-Chronic Toxicity Studies
As part of the preclinical Good Laboratory Practice (GLP)-compliant
safety pharmacology and toxicity program for rVIII-SingleChain, a series
of studies were conducted in different animal species.
Local Tolerance
Local tolerance was assessed in rabbits after administration of
rVIII-SingleChain by different routes. Nine New ZealandWhite rabbits
(aged 16–18 weeks; weighing 3.15–3.84 kg) each received a single
injection of both rVIII-SingleChain (at a nominal concentration of
359 IU/mL) and placebo on Day 1. Three animals received a single in-
travenous administration of 1.0 mL into the lateral ear vein of the
right ear. Three animals received a single intra-arterial administration
of 1.0 mL against the blood ﬂow into the median auricular artery of
the right ear. Three animals received a single perivenous administra-
tion of 0.2 mL alongside the lateral ear vein of the right ear. For each
rVIII-SingleChain administration route tested, the same volume of
control solution (isotonic saline solution [0.9%]) was injected into
the corresponding site in the left ear at the same time. The animals
were observed for signs of ill health or toxicity at least twice daily
for four days. Examination of the injection sites was made one hour
after injection and approximately 24, 48, and 72 hours later. A histo-
logic examination was performed on both ears and surrounding tis-
sues for each animal.
Single-Dose Toxicity Studies
The potential for systemic toxicity and the toxicokinetic proﬁle of
rVIII-SingleChain after a single administration was assessed in Crl:CD
(SD) rats and cynomolgus monkeys. Exposure to and toxicokinetics ofthe compound were assessed using two methods, a direct analysis of
rVIII-SingleChain concentrations by enzyme-linked immunosorbent
assay (ELISA) (Cedarlane Laboratories, Hornby, Ontario, Canada) in
rats and a chromogenic measurement of FVIII activity (Coamatic®
Factor VIII, Chromogenix, Milan, Italy) in monkeys. Three groups of
rats each comprising ﬁve males and ﬁve females, and three groups
of monkeys each comprising three males and three females received
a single dose of rVIII-SingleChain 50, 250, or 1500 IU/kg into the left
or right caudal and cephalic/saphenic vein, respectively on Day 1.
For both rats and monkeys, the similarly constituted control groups
received isotonic saline (0.9%). The rats were observed for a total of
ﬁve days and the monkeys for 10 days. In the monkey study, two
males and two females from each group were killed on Day 6 (interim
kill, prior to the onset on a confounding immune response against the
human protein), and one male and one female from each group were
killed on Day 11. In the rat study, a further three males and three fe-
males were allocated to the control group, and nine males and nine
females were allocated to each treated group and were used for
toxicokinetic evaluation (satellite animals). During the study, clinical
condition, bodyweight, food consumption (rat only), hematology,
blood chemistry, toxicokinetics, urinalysis, organ weight, macro-
pathology, and histopathology investigations were undertaken. In
rats, rVIII-SingleChain was not detected in the plasma samples from
control animals by ELISA so correction for endogenous FVIII was not
undertaken in toxicokinetic studies. In monkeys, as untreated animals
showed detectable endogenous FVIII concentrations, the endogenous
FVIII concentration measured before dosing was subtracted from the
FVIII concentration measured after dosing to obtain corrected plasma
FVIII levels.Repeated-Dose Toxicity Studies
The systemic toxic potential and toxicokinetics of repeated doses
of rVIII-SingleChain were also assessed in Crl:CD (SD) rats and
cynomolgus monkeys. Over 28 days, three groups, each comprising 10
male and 10 female rats received rVIII-SingleChain at doses of 50, 250,
or 1250 IU/kg/day, and three groups of three male and three female
monkeys received doses of 50, 150, or 500 IU/kg. For both rats and
monkeys, the similarly constituted control groups received isotonic sa-
line (0.9%). A further one male and one female monkey were assigned
to each group; these animals were dosed for ﬁve days and were killed
on Day 6. In the rat study, a further ﬁve male and ﬁve female rats
were assigned to each of the control and 1500 IU/kg groups; these ani-
mals were treated for four weeks followed by 14 days without treat-
ment to assess recovery from any treatment-related effects. A further
three male and three female rats were allocated to the control group
and nine males and nine females were allocated to each treated
group and were used for toxicokinetic evaluation (satellite ani-
mals). During the studies, mortality (rats only), clinical condition,
body weight, food consumption (rats only), ophthalmic examina-
tions, electrocardiogram (monkeys only), blood pressure (monkeys
only), hematology, blood chemistry, neurobehavioral assessment
(Irwin screen; rats only), toxicokinetics, anti-drug antibody (ADA)
development, urinalysis, organ weight, macropathology, and histo-
pathology investigations were undertaken.Safety Pharmacology
A study was conducted to assess cardiovascular endpoints under
telemetered conditions in monkeys that received rVIII-SingleChain at a
cumulative dose of 1550 IU/kg. Four telemetered monkeys (two males
and two females) received three separate infusions of rVIII-SingleChain
(50 [ﬁrst infusion], 250 [second], and 1250 IU/kg [third]) over three
30-minute periods. The animals also received vehicle (0.9% saline) as
control.
Table 1
Relative potency estimated from an analysis of covariance model for total blood loss in
FVIII knockout mice (hemophilia A model). Mice received intravenous administrations
of 1–150 IU/kg of rVIII-SingleChain, B-domain deleted rFVIII (ReFacto AF®), or full-length
rFVIII (Helixate®, Advate®) in a tail-clip model (n = 10–20 per group).
Treatment Comparator Relative potency 90% conﬁdence interval
rVIII-SingleChain Helixate® 1.04 0.52–2.08
rVIII-SingleChain ReFacto AF® 1.34 0.67–2.77
rVIII-SingleChain Advate® 2.15 1.23–3.98
rFVIII = recombinant factor VIII.
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Preclinical Efﬁcacy: In vivo Characteristics of rVIII-SingleChain vs
Licensed Human rFVIII
Tail-Clip Model
Overall, a comparable effect on primary hemostasis endpoints was
found with rVIII-SingleChain compared with licensed FVIII products
in the tail-clip model in hemophilia A mice (Fig. 1).
With respect to total blood loss, the estimated potency of rVIII-
SingleChain was similar to that of Helixate® (factor 1.04) and slightly
higher than that of ReFacto AF® (factor 1.34) and Advate® (factor
2.15) (Table 1 and Fig. 1). These minor differences between rVIII-
SingleChain and the licensed FVIII concentrates (used as active com-
parators) were not statistically signiﬁcant (p N 0.4), indicating an
equipotent effect.
The percentage of animals in which hemostasis occurred was sim-
ilar for the compared products. All human rFVIII products showed a
dose-dependent effect on this endpoint. The dose dependency of he-
mostasis was signiﬁcant (p b 0.0001) in all comparisons. The esti-
mates of the relative potency values are summarized in Table 2.
With respect to the percentage of animals achieving hemostasis, the
estimated potency of rVIII-SingleChain was the same as that of
Helixate® (factor 1.00), and similar to ReFacto AF® (factor 1.17), and
Advate® (factor 0.87). The differences between rVIII-SingleChain and
ReFacto AF® or Advate® were not statistically signiﬁcant (p N 0.7 for
all comparisons) (data not shown).Thromboelastography, Thrombin Generation Assay, Activated Partial
Thromboplastin Time, and FVIII Activity
In the thromboelastography analysis, rVIII-SingleChain, and Advate®
(both 20 IU/kg) corrected all ROTEM® parameters, including CT, CFT,
maximum velocity, and alfa angle (Fig. 2). Estimated ratios of thrombo-
elastographic parameters for rVIII-SingleChain:full-length rFVIII were
1.27 (90% CI: 1.11–1.48; p b 0.01) for CT, 1.18 (90% CI: 0.97–1.47;
p = 0.16) for CFT, 0.86 (90% CI: 0.66–1.17; p = 0.36) for maximum ve-
locity, and 0.92 (90% CI: 0.84–1.02; p = 0.16) for alfa angle. In addition
to the thromboelastographic parameters shown in Fig. 2, both active
drugs corrected mean time to maximum velocity (759 and 598 vs
3040 s for rVIII-SingleChain and Advate® vs vehicle, respectively),
mean maximum clot ﬁrmness (55.6 and 56.0 vs 43.0 mm), and mean900
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Fig. 1. Mean total blood loss in FVIII knockout mice (hemophilia A model). Mice re-
ceived intravenous administrations of 1–150 IU/kg of rVIII-SingleChain, BDD (ReFacto
AF®), or full-length rFVIII (Helixate®, Advate®) in a tail-clip model (n = 10–20 per
group; FVIII-deﬁcient mice). Data shown are mean ± SEM. BDD = B-domain deleted;
rFVIII = recombinant factor VIII.time to maximum clot ﬁrmness (3550 and 3529 vs 2649 s) compared
with vehicle.
In the TGA, rVIII-SingleChain and full-length rFVIII (both 20 IU/kg)
corrected all thrombin generation parameters (Fig. 3). For lag time,
ETP, and time to thrombin peak, endogenous background activity
was only measurable in some individual animals in the vehicle
group. The effects of rVIII-SingleChain and full-length rFVIII on
thrombin peak (mean ± standard deviation (SD)) were similar
(372 ± 46 and 363 ± 47 nM, respectively), with an estimated ratio
of 1.02 (90% CI: 0.93–1.13) between the two products. In comparison,
the mean ± SD thrombin peak for vehicle was 3.1 ± 5.7 nM. Estimat-
ed ratios of thrombin generation parameters for rVIII-SingleChain:
full-length rFVIII were 1.13 (90% CI: 0.91–1.44) for lag time, 1.02 (90%
CI: 0.96–1.08) for ETP, and 1.12 (90% CI: 0.93–1.35) for time to throm-
bin peak; all ratios were non-signiﬁcant.
To further investigate the minor and apparently signiﬁcant differ-
ence in CT between rVIII-SingleChain and full-length rFVIII that was
evident in the thromboelastography analysis, aPTT values were mea-
sured in plasma derived from FVIII-deﬁcient mice (ex vivo) that were
treated with both rFVIII products. As shown in Fig. 4, there was no sig-
niﬁcant difference in aPTT between the rVIII-SingleChain (geometric
mean 44.0 s) and full-length rFVIII (40.8 s; p = 0.08) groups. The
90% CI for the ratio of the geometric means extended from 1.01 to
1.16. However, aPTT was signiﬁcantly reduced in both groups versus
vehicle (rVIII-SingleChain: p = 0.006; full-length rFVIII: p = 0.001).
Administration of 20 IU/kg rVIII-SingleChain or full-length rFVIII led to
measurable FVIII chromogenic activity in plasma. Vehicle-treated animals
showed values below the limit of detection (b0.015 IU/mL). Mean values
(±SD) derived from 16 animals treated with either rVIII-SingleChain or
full-length rFVIII were 0.248 ± 0.052 IU/mL (range: 0.08–0.29 IU/mL)
and 0.217 ± 0.06 IU/mL (range: 0.04–0.28 IU/mL), respectively with
an 11% higher chromogenic factor VIII activity for rVIII-SingleChain
(p = 0.007). However, chromogenic factor VIII activity of the two
products was equivalent (within 80% to 125%; p = 0.002) and the 90%
CIs of the mean ratio extended from 104% to 118%.
Safety and Tolerability
Thrombogenicity in Rabbits
The positive aPCC control (FEIBA NF 500®) showed the greatest
procoagulant effect in both jugular veins compared with rVIII-
SingleChain, two-chain BDD rFVIII (ReFacto AF®), and saline solution
(negative control). The mean thrombus incidence score with rVIII-Table 2
Relative potency of rVIII-SingleChain and comparators estimated from a logistic
regression model for percentage of FVIII knockout mice in which hemostasis
occurred (hemophilia A model). Mice received intravenous administrations of
1–150 IU/kg of rVIII-SingleChain, B-domain deleted (ReFacto AF®), or full-length rFVIII
(Helixate®, Advate®) in a tail-clip model (n = 10–20 per group; FVIII-deﬁcient mice).
Treatment Comparator Relative potency 90% conﬁdence interval
rVIII-SingleChain Helixate® 1.00 0.46–2.17
rVIII-SingleChain ReFacto AF® 1.17 0.53–2.65
rVIII-SingleChain Advate® 0.87 0.45–1.70
rFVIII = recombinant factor VIII.
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range, but was not signiﬁcantly different from the negative control
in either jugular vein (Table 3). Indicative of a minimal biologic effect800
600
400
200
0
C
En
do
ge
no
us
 th
ro
m
bi
n
po
te
nt
ia
l
Vehiclea rVIII- SingleChain
Full-length 
rFVIII
5
4
3
2
1
0
La
g 
tim
e 
(m
inu
tes
)
Vehiclea rVIII- SingleChain
Full-length 
rFVIII
A
Fig. 3. Thrombin generation assay results in FVIII knockout mice (hemophilia A m
or full-length rFVIII (Advate®), or vehicle (where measurable). (A) Lag time (n = 10
(ETP; n = 10/group), and (D) time to thrombin peak (n = 10/group). Data shown are mea
in the vehicle group only. rFVIII = recombinant factor VIII.level, rVIII-SingleChain only showed signiﬁcantly (p b 0.05) greater
thrombus formation compared with negative control at the highest
dose (1000 IU/kg) and only in the left jugular vein when submittedB
Pe
ak
 th
ro
m
bi
n 
(nM
)
500
400
300
200
100
0
rVIII- 
SingleChainVehicle
Full-length 
rFVIII
Ti
m
e 
to
 p
ea
k 
(m
inu
tes
)
D
6
4
2
0
Vehiclea rVIII- SingleChain
Full-length 
rFVIII
odel). Mice received intravenous administrations of 20 IU/kg of rVIII-SingleChain
/group), (B) thrombin peak (n = 10/group), (C) endogenous thrombin potential
n ± SD. aEndogenous background activity was measurable in some individual animals
80
60
40
20
0
Vehicle
Ac
tiv
at
ed
 p
ar
tia
l t
hr
om
bo
pl
as
tin
 
tim
e 
(se
co
nd
s)
rVIII-
SingleChain
Full-length 
rFVIII
Fig. 4. aPTT (ex vivo) following administrationof 20 IU/kg rVIII-SingleChain (n = 16)
and Advate® (n = 15) in FVIII-deﬁcientmice versus vehicle (n = 10).Data shown are
mean ± SD. aPTT = activated partial thromboplastin time; FVIII = factor VIII.
285S.B. Zollner et al. / Thrombosis Research 132 (2013) 280–287to the longer stasis time (20 minutes) (i.e., more stringent condi-
tions). Administration of BDD rFVIII 500 IU/kg showed an intermedi-
ate effect, similar to that observed with rVIII-SingleChain at doses of
500 and 1000 IU/kg. As with rVIII-SingleChain, this marginal effect
was not signiﬁcantly different from the negative control (Table 3).
Signiﬁcant (p b 0.05) differences were observed between the pos-
itive (FEIBA NF 500®) and negative controls for dry weight of throm-
bus (Table 3). In contrast, rVIII-SingleChain at all doses tested and
BDD rFVIII 500 IU/kg did not show any signiﬁcant differences com-
pared with the negative control (Table 3). Dry weight of thrombus
was also similar between rVIII-SingleChain (all doses) and BDD rFVIII
500 IU/kg (Table 3). The percentage PTF was greater in male than fe-
male rabbits (data not shown).
Therefore, in comparison with vehicle (control), rVIII-SingleChain
showed a minimal procoagulant effect only at the highest dose of
1000 IU/kg, with no statistically signiﬁcant effects at lower doses of
150, 300, or 500 IU/kg.Acute and Sub-Chronic Toxicity Studies
In rabbits, intravenous, intra-arterial, and perivenous injections of
rVIII-SingleChain were well tolerated with no local or systemic signs
of reaction to treatment. No adverse effects were found withTable 3
Procoagulant activity of rVIII-SingleChain and BDD rFVIII (ReFacto AF®) compared with posit
rabbits by different endpoints (Wessler modiﬁcation).
Right jugular vein
Treatment Dose
(IU/kg)
Global thrombus
incidence scorea
Mean dry weight o
thrombus (mg) ±
Saline (negative control) – 1 0.02 ± 0.025
aPCC (positive control) 200 21d 18.12 ± 7.111c
BDD rFVIII 500 2 0.07 ± 0.067
rVIII-SingleChain 150 0 0.00 ± 0.000
300 4 0.10 ± 0.155
500 0 0.00 ± 0.000
1000 4 0.13 ± 0.084
aPCC = activated prothrombin complex concentrate; BDD = B-domain deleted; PTF = po
a Scoring of thrombus incidence: blood = 0; ﬁbrin network = 1; ≥1 small thrombus =
b PTF (potentiation of thrombus formation) calculated as:
rVIII SingleChain mDWTð Þ– negative control group mDWTð Þ
positive control group mDWTð Þ– negative control group mDWTð Þ  100
Where mDWT is the mean dry weight of thrombus. A DWT value of 0.1 mg or less was con
c Statistically signiﬁcant per Student–Newman–Keuls test (p b 0.05).
d Statistically signiﬁcant per Mann–Whitney test (p b 0.05).rVIII-SingleChain at single doses of 50, 250, or 1500 IU/kg in CD rats
or cynomolgus monkeys (Table 4).
In rats, toxicokinetic investigations conﬁrmed that the maximum
concentration (Cmax) of FVIII and extent (AUC and AUC0–24h) of system-
ic exposure, increased dose proportionally with escalating doses over
the range 50–1500 IU/kg: mean Cmax values ranged from 0.88 to
8.26 IU/mL; mean AUC values ranged from 3.74 to 31.44 IU · h/mL;
and mean AUC0–24h values ranged from 1.27 to 30.44 IU · h/mL. The
AUC parameters showed higher values for males than for females at
all doses tested, but Cmax values were in a comparable range for
both sexes. The time taken to achieve Cmax (tmax) values for females
and males was similar across all doses tested. Over the doses tested,
the half-life (t1/2) values showed no indication of dose- or sex
dependency.
In cynomolgus monkeys, the measured rVIII-SingleChain plasma
concentrations, based on chromogenic activity and corrected for endog-
enous FVIII levels, increased with escalating doses. Dose-proportional
exposure of the treated animals to rVIII-SingleChain was clearly
shown in the single-dose toxicity study. The Cmax and AUC0-last in-
creased with dose for both males and females and the increase in
exposure was proportional to the dose after a single administration of
up to 1500 IU/kg of rVIII-SingleChain: mean Cmax values ranged from
1.51 to 38.8 IU/mL and mean AUC0-last values ranged from 13.1 to
293 IU · h/mL. Higher exposure was observed at all dose levels in male
versus female monkeys. Mean tmax was 0.25 hours for all doses and in
both sexes. Similar to the study in rats, the mean t1/2 values showed no
indication of dose- or sex dependency over the dose range tested.
In the repeated-dosing studies, no systemic toxicity related to
rVIII-SingleChain was observed following sub-chronic dosing of
rats and cynomolgus monkeys over 28 days at dose levels up to
1250 IU/kg (Table 4). The investigation of potential neurobehavioral
effects of rVIII-SingleChain in rats (Irwin test) did not reveal any
treatment-related macroscopic or histopathologic changes indicative
of an effect on the central nervous system. In rats and monkeys, there
were no treatment-related effects for the safety endpoints assessed.
Exposure to and toxicokinetics of rVIII-SingleChain were assessed
using two methods: a direct analysis of rVIII-SingleChain concentra-
tions by ELISA in plasma samples from rats and a chromogenic mea-
surement of FVIII activity in plasma samples from monkeys. In the
rat repeated-dosing study, the rVIII-SingleChain concentrations mea-
sured in most of the plasma samples obtained on Day 28 were found
to be below the lower limit of quantiﬁcation, rendering it impossible
to perform toxicokinetic evaluation. In the single-dose rat study (see
above), dose-proportional pharmacokinetics were demonstrated. Theive (aPCC; FEIBA NF 500®) and negative (saline solution) controls after venous stasis in
Left jugular vein
f
SD
PTFb (%) Global thrombus
incidence scorea
Mean dry weight of
thrombus (mg) ± SD
PTFb (%)
0 3 0.09 ± 0.054 0
100 23d 22.12 ± 5.502c 100
0 6 0.25 ± 0.115 1
0 0 0.00 ± 0.000 0
0 4 0.17 ± 0.117 0
0 6 0.20 ± 0.0093 0
1 13d 1.47 ± 0.398 6
tentiation of thrombus formation; rFVIII = recombinant factor VIII.
2; non-occlusive thrombus = 3; occlusive thrombus = 4.
sidered to be equal to 0.
Table 4
Good Laboratory Practice-compliant safety pharmacology and toxicity program for
rVIII-SingleChain in three different preclinical species.
Study type Species rVIII-SingleChain
dose range
(IU/kg)
Outcome
Acute, single dosea Rat, monkey 50–1500 No adverse
ﬁndings
Local tolerance Rabbit 21–105 No adverse
ﬁndings
Sub-chronic, repeated
dosea (incl. Irwin test)
Rat 50–1250 No adverse
ﬁndings
Sub-chronic, repeated dosea
(incl. CV parameters)
Monkey 50–500 No adverse
ﬁndings
CV endpoints by telemetrya Monkey 50–1250 No adverse
ﬁndings
CV = cardiovascular; FVIII = factor VIII.
a Studies encompassing plasma analysis by FVIII:Ag (ELISA) or FVIII activity (chromogenic
assay) for toxicokinetic assessment.
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50, 150, or 500 IU/kg indicated that on Day 1 the measured rVIII-
SingleChain plasma concentrations increased with increasing dose.
Cmax and AUC0–24 increased with dose for both males and females
and the increase in exposure was proportional to the dose after a sin-
gle administration of up to 1500 IU/kg of rVIII-SingleChain. There was
no effect of sex on plasma concentrations and toxicokinetic parame-
ters. At Day 6 of the repeated-dosing study in rats and monkeys,
there was no evidence of a measured immune response to rVIII-
SingleChain. However, at Day 28 (the end of both repeated dosing
studies), the majority of animals in all dose groups had developed
neutralizing and non-neutralizing ADAs against the heterologous
human rVIII-SingleChain. Consequently, treated animals had FVIII
levels that had signiﬁcantly decreased from their pre-treatment
values, as well as during all sampling time points after the last appli-
cation of rVIII-SingleChain. In the cardiovascular safety study in
telemetered monkeys, parameters such as arterial blood pressure,
left ventricular systolic pressure, left ventricular end diastolic pres-
sure, cardiac output, and stroke volume, were considered unaffected
by rVIII-SingleChain treatment (Table 4) after in-depth analysis.
No effects were observed throughout the study period on ECG
(lead II) waveform morphology after animals received control or
rVIII-SingleChain. Furthermore, dose formulation and toxicokinetic
analysis revealed proper reconstitution and adequate exposure of all
animals to rVIII-SingleChain (data not shown).Discussion
In this series of preclinical studies, rVIII-SingleChain (1–150 IU/kg)
demonstrated equivalent hemostatic activity compared with full-
length (Helixate® and Advate®) and BDD rFVIII (ReFacto AF®), with
minor differences in total blood loss in a hemophilia A mouse tail-clip
bleedingmodel [17]. In addition, the percentage of animals with hemo-
stasis was comparable between products in this well-established and
relevant animal model, reﬂecting the clinical situation in patients
with hemophilia A with regard to major injury or life-threatening trau-
ma. In an assessment of hemostasis kinetics in hemophilia A mice,
rVIII-SingleChain (20 IU/kg) and full-length rVIII (Advate® 20 IU/kg)
exhibited comparable FVIII hemostatic activity, correcting individual
hemostatic efﬁcacy parameters (thromboelastographic, aPTT, and
thrombin generation variables) to a similar degree.
In the thromboelastography analysis, the minor and apparently
signiﬁcant difference in CT observed for rVIII-SingleChain compared
with Advate® using this highly sensitive technique was not relevant
to the hemostatic efﬁcacy seen in vivo (i.e., in the tail-clip model).
This observation is corroborated by results from TGA analysis, asimilarly sensitive method, which did not show a signiﬁcant differ-
ence in all parameters tested: lag time, thrombin peak, endogenous
thrombin potential, and time to thrombin peak. Speciﬁcally, in the pa-
rameters that measure the early phase of hemostasis there was no
signiﬁcant difference. Furthermore, there was no signiﬁcant differ-
ence in the measured aPTT with rVIII-SingleChain versus full-length
rFVIII and both showed bioequivalence when monitoring chromo-
genic FVIII activity.
An excellent safety proﬁle was observed across all studies in three
different, pharmacologically relevant animal species (monkey, rabbit,
and rat), with no toxicologically relevant adverse effects after admin-
istration of rVIII-SingleChain. This observation is consistent with
preclinical safety and toxicity data described for marketed BDD rFVIII
products such as ReFacto AF®/Xyntha® [18,19] as well as full-length
rFVIII products such as Advate® [20] and Kogenate® [21]. The excel-
lent tolerability and safety characteristics of rVIII-SingleChain were
observed at doses up to 1500 IU/kg in the GLP-compliant safety and
toxicology program. This represents a safety margin of ≥10-fold
above the anticipated standard human dose of approximately
50 IU/kg/day, and even covers higher daily human doses of
75–100 IU/kg in clinical use for the treatment of life-threatening
hemorrhages and after major surgery [18].
FVIII activity levels (as geometric means) in plasma samples from
the rabbit study ranged from 2 IU/mL to 19 IU/mL across dose levels
of 150 IU/kg to 1000 IU/kg. Most importantly, even at high doses
exceeding the proposed human standard dose by a factor of 10
and giving rise to FVIII levels of N1.5 IU/mL (odds ratio 4–6), these
supra-therapeutic investigations found no increase in prothrombotic
risk with rVIII-SingleChain, while exhibiting procoagulant activity
comparable to commercial BDD and full-length rFVIII. A thrombogenic
risk associated with high plasma FVIII levels (250% FVIII activity) has
previously been demonstrated in rodents [22]. In this thrombophilia
mouse model, a mild injury was inﬂicted at the carotid artery by irradi-
ation in combination with the intravenously injected dye rose bengal.
However, in the current safety and toxicity program, thrombus forma-
tion was induced by stasis of jugular veins in rabbits. Furthermore, the
current preclinical investigation used a venous stasis model to investi-
gate the thrombogenic potential of rVIII-SingleChain in rabbits accord-
ing to Giles et al. [16] based on an initial study by Wessler et al. [23].
The Wessler test, in which induced hypercoagulability is combined
with local venous stasis, has been used extensively for over 40 years
and has signiﬁcantly contributed to our understanding of the pathogen-
esis of venous thromboembolism and its prevention. In addition, it has
proven invaluable for assessing the thrombogenicity of various blood
products, as well as for assaying the effectiveness of heparin and hepa-
rin functions [23,24]. A large number of different animal species have
been used to study venous thrombosis and themethod of thrombus for-
mation also varies, including differences in the means of inducing vas-
cular wall damage, stasis of blood, and local activation of coagulation.
Although there is ample variation in these methods, most techniques
may be considered as a variation of theWessler model, which produces
temporary venous stasis by ligating an appropriate vein and taking
thrombosis incidence and thrombus dry weight as parameters for eval-
uation and comparison. Thus, in the context of investigating exaggerat-
ed procoagulant activity as a risk factor for thrombosis, both animal
models exploring venous and arterial thrombosis appear relevant. Ele-
vated plasma FVIII levels are recognized as an independent risk factor
for both arterial and venous thrombosis in humans exhibiting a
thrombophilic phenotype [25].
As human rFVIII proteins represent a heterologous protein species
to animals, obstacles will be encountered during preclinical pharma-
cology and safety investigations. As expected, neutralizing and
non-neutralizing ADAs against rVIII-SingleChain were observed at
the end of the repeated-dosing studies in the majority of the rats
and monkeys that received rVIII-SingleChain. This development of
ADAs indicates that rVIII-SingleChain functions as an antigen in
287S.B. Zollner et al. / Thrombosis Research 132 (2013) 280–287rodents and non-rodent animals as a consequence of its heterologous
nature as a human protein. In the rat repeated-dosing study, the for-
mation of ADAs after four weeks of daily treatment was thought to be
a reason for the concentrations of drug remaining below the lower
limit of quantiﬁcation, meaning that toxicokinetics could not be
assessed. Furthermore, this lack of exposure makes toxicity data de-
rived from longer-term chronic toxicity studies tenuous. For this rea-
son, chronic toxicity studies of 3–6 months in duration, even though
recommended for biotechnology-derived pharmaceuticals by regula-
tory guidelines i.e., ICH guideline S6 (R1), were not undertaken in
this series of preclinical studies. Formation of alloantibodies is consis-
tent with observations reported from the preclinical development
of marketed FVIII concentrates, including BDD FVIII [18,19] and
full-length rFVIII products [20]. As reported for other marketed
human rFVIII concentrates (ReFacto AF®, Advate®), the ADA response
to rVIII-SingleChain correlated with increased aPTT in monkeys, which
indicates cross-reactivity of inhibitory ADAs to monkey FVIII clotting
factor activity. In accordance with marketed FVIII concentrates, the
potential for immunogenicity in humans will be assessed during the
rVIII-SingleChain clinical program.
Unlike the currently marketed rFVIII products, which have a
two-chain structure, rVIII-SingleChain is a unique single-chain re-
combinant FVIII. Following activation, the rFVIIIa produced from
rVIII-SingleChain is structurally comparable to that formed from
two-chain endogenous FVIII [13]. When produced endogenously,
FVIII is secreted from hepatic and endothelial cells and processed to
a heterodimer consisting of a light chain and a heavy chain joined
by a metal ion bridge [26]. Under certain conditions, this structure
can dissociate, resulting in the formation of inactive dissociated
FVIII chains [27]. The two-chain design, although physiologic for en-
dogenous FVIII, represents a labile conﬁguration in the manufacturing
environment, which can result in the formation of inactive dissociat-
ed FVIII chains. Therefore, the novel single-chain design could provide
a basis for beneﬁcial product characteristics such as high intrinsic sta-
bility and molecular integrity. Whether this high molecular stability
and integrity when associated with VWF (which protects and shields
FVIII in systemic circulation) results in a reduced immunogenic po-
tential will need to be investigated in clinical use.
In conclusion, this preclinical program demonstrates convincing
preclinical efﬁcacy for rVIII-SingleChain and provides a clear indication
of its excellent safety proﬁle and tolerability. The investigations did not
reveal any safety concerns and support the evidence necessary for pro-
ceeding into human trials. The rVIII-SingleChain AFFINITY clinical trial
program has now commenced with recruitment into and dosing of
rVIII-SingleChain in a Phase I/III study.
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